Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.

Swart JF, Barug D, Möhlmann M, Wulffraat NM.

Expert Opin Biol Ther. 2010 Dec;10(12):1743-52. doi: 10.1517/14712598.2010.532785. Epub 2010 Oct 28. Review.

PMID:
20979564
2.

Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.

Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, Kunkel G, Schlesinger M, Bohnsack J.

J Clin Rheumatol. 2009 Jun;15(4):161-4. doi: 10.1097/RHU.0b013e3181a4f459.

PMID:
19363453
3.

The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.

Kalliolias GD, Liossis SN.

Expert Opin Investig Drugs. 2008 Mar;17(3):349-59. doi: 10.1517/13543784.17.3.349 . Review.

PMID:
18321234
4.

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.

Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC.

Arthritis Rheum. 2011 Feb;63(2):545-55. doi: 10.1002/art.30128.

5.

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.

Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J; Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP).; Club Rhumatismes et Inflammation (CRI)..

Ann Rheum Dis. 2008 Mar;67(3):302-8. Epub 2007 Oct 18.

PMID:
17947302
6.

Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.

Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, Allen R, Harville T, Sun YN, Bevirt T, Aras G, Appleton B.

Clin Rheumatol. 2009 Feb;28(2):129-37. doi: 10.1007/s10067-008-0995-9. Epub 2008 Sep 3.

PMID:
18766426
7.

Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).

Hedrich CM, Bruck N, Fiebig B, Gahr M.

Rheumatol Int. 2012 Nov;32(11):3525-30. doi: 10.1007/s00296-011-2249-4. Epub 2011 Nov 15.

PMID:
22083619
8.

Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA).

Ohlsson V, Baildam E, Foster H, Jandial S, Pain C, Strike H, Ramanan AV.

Rheumatology (Oxford). 2008 Apr;47(4):555-6. doi: 10.1093/rheumatology/ken030. Epub 2008 Mar 5. No abstract available.

PMID:
18321945
9.

Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease.

Woo P.

Ann Rheum Dis. 2008 Mar;67(3):281-2. doi: 10.1136/ard.2007.082859. No abstract available.

PMID:
18292104
11.

[Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis].

Botsios C, Sfriso P, Furlan A, Ostuni P, Biscaro M, Fiocco U, Todesco S, Punzi L.

Reumatismo. 2007 Jan-Mar;59(1):32-7. Italian.

12.

Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series.

Record JL, Beukelman T, Cron RQ.

J Rheumatol. 2011 Jan;38(1):180-1. doi: 10.3899/jrheum.100726. No abstract available.

PMID:
21196588
13.

The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.

Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, ten Cate R, Hoppenreijs EP, Hansmann S, Moncrieffe H, Ursu S, Wedderburn LR, Roth J, Foell D, Wittkowski H.

Ann Rheum Dis. 2012 Jun;71(6):974-80. doi: 10.1136/annrheumdis-2011-200598. Epub 2012 Jan 20.

PMID:
22267331
14.

An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX).

Jung N, Hellmann M, Hoheisel R, Lehmann C, Haase I, Perniok A, Hallek M, Rubbert A.

Clin Rheumatol. 2010 Oct;29(10):1169-73. doi: 10.1007/s10067-010-1504-5. Epub 2010 Jun 9.

PMID:
20532937
15.

[Anakinra treatment in refractory systemic onset juvenile arthritis].

Garrido Colino C, Saavedra Lozano J.

An Pediatr (Barc). 2008 Mar;68(3):305-6. Spanish. No abstract available.

16.
17.

[New treatments for idiopathic juvenile arthritis].

Bader-Meunier B, Quartier P.

Arch Pediatr. 2009 Dec;16(12):1607-11. doi: 10.1016/j.arcped.2009.07.020. Epub 2009 Nov 5. French.

PMID:
19896351
18.

The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.

Cohen SB.

Rheum Dis Clin North Am. 2004 May;30(2):365-80, vii. Review.

PMID:
15172046
19.

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.

Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P.

Arthritis Rheum. 2010 Jan;62(1):258-67. doi: 10.1002/art.25057.

20.

Supplemental Content

Support Center